Compare Johnson & Johnson (JNJ) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Microsoft — how do they compare? Johnson & Johnson trades at $257.85 (market cap $626.09B), while Microsoft trades at $499.8 (market cap $3.74T). The key difference: Microsoft is far larger — about 6× Johnson & Johnson's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | MSFT | |
|---|---|---|
Market Cap | $626.09B | $3.74T |
Volume | 6,156,228 | 36,654,621 |
Sector | Health | Technology |
52-Week High | $267.24 | $542.07 |
52-Week Low | $172.78 | $352.83 |
Enterprise Value | $654.37B | $3.72T |
Dividend Yield | 2.06% | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Microsoft (MSFT) trades at $506.06, up 1.21% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Recent news highlights Microsoft's AI leadership and Azure growth potential, though concerns about capital expenditures persist. The stock trades near pivot point resistance at $507 with strong support at $500.
Outlook remains positive with 80% analyst buy ratings and $552.73 consensus target offering 9% upside. Key opportunities include AI integration and cloud growth, while risks involve competitive pressures and execution on large capital investments. The combination of strong fundamentals and technical momentum supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
